B W Bode

Summary

Publications

  1. ncbi request reprint Diabetes management in the new millennium using insulin pump therapy
    Bruce W Bode
    Atlanta Diabetes Associates, 77 Collier Road, NW, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Metab Res Rev 18:S14-20. 2002
  2. ncbi request reprint Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy
    Bruce W Bode
    Atlanta Diabetes Associates and Piedmont Hospital, Atlanta, Georgia, USA
    Endocr Pract 10:71-80. 2004
  3. ncbi request reprint Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation
    Paul C Davidson
    Atlanta Diabetes Associates, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Care 28:2418-23. 2005
  4. ncbi request reprint Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system
    Bruce W Bode
    Atlanta Diabetes Associates, Atlanta, Georgia 30319, USA
    Endocr Pract 11:157-64. 2005
  5. ncbi request reprint Demonstrations and discussions of continuous glucose monitors
    Bruce W Bode
    FACE, Atlanta Diabetes Association, Atlanta, Georgia 30309, USA
    Diabetes Technol Ther 7:805-8. 2005
  6. doi request reprint Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30318, USA
    Hosp Pract (1995) 41:72-84. 2013
  7. doi request reprint An overview of the pharmacokinetics, efficacy and safety of liraglutide
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Res Clin Pract 97:27-42. 2012
  8. doi request reprint Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30309, USA
    Hosp Pract (1995) 37:7-21. 2009
  9. ncbi request reprint Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
    B W Bode
    Atlanta Diabetes Associates, Georgia 30309, USA
    Diabetes Care 24:69-72. 2001
  10. doi request reprint Intensive insulin therapy and insulin pumps
    Bruce W Bode
    Diabetes Resource Center, Piedmont Hospital in Atlanta, GA, USA
    Postgrad Med 112:17-21. 2002

Detail Information

Publications29

  1. ncbi request reprint Diabetes management in the new millennium using insulin pump therapy
    Bruce W Bode
    Atlanta Diabetes Associates, 77 Collier Road, NW, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Metab Res Rev 18:S14-20. 2002
    ..The recent introduction of methods for continuous glucose monitoring provides a new means to optimize the basal and bolus capabilities of CSII and offers the hope of the development of a feedback-controlled artificial pancreas...
  2. ncbi request reprint Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy
    Bruce W Bode
    Atlanta Diabetes Associates and Piedmont Hospital, Atlanta, Georgia, USA
    Endocr Pract 10:71-80. 2004
    ..To describe indications for intravenous (IV) insulin infusion therapy and glycemic thresholds, discuss methods and protocols, and promote use of and access to IV insulin infusion therapy for all appropriate patients in the hospital setting...
  3. ncbi request reprint Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation
    Paul C Davidson
    Atlanta Diabetes Associates, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Care 28:2418-23. 2005
    ..The published methods for administering the insulin are complex and are usually limited to intensive care units with a low patient-to-nurse ratio...
  4. ncbi request reprint Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system
    Bruce W Bode
    Atlanta Diabetes Associates, Atlanta, Georgia 30319, USA
    Endocr Pract 11:157-64. 2005
    ....
  5. ncbi request reprint Demonstrations and discussions of continuous glucose monitors
    Bruce W Bode
    FACE, Atlanta Diabetes Association, Atlanta, Georgia 30309, USA
    Diabetes Technol Ther 7:805-8. 2005
  6. doi request reprint Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30318, USA
    Hosp Pract (1995) 41:72-84. 2013
    ....
  7. doi request reprint An overview of the pharmacokinetics, efficacy and safety of liraglutide
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Res Clin Pract 97:27-42. 2012
    ..The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data...
  8. doi request reprint Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge
    Bruce Bode
    Atlanta Diabetes Associates, Atlanta, GA 30309, USA
    Hosp Pract (1995) 37:7-21. 2009
    ..This review examines the challenges to achieving glycemic control in the hospital setting and summarizes clinical data on the efficacy and safety of incretin-based therapies in their use in the hospital and after discharge...
  9. ncbi request reprint Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
    B W Bode
    Atlanta Diabetes Associates, Georgia 30309, USA
    Diabetes Care 24:69-72. 2001
    ....
  10. doi request reprint Intensive insulin therapy and insulin pumps
    Bruce W Bode
    Diabetes Resource Center, Piedmont Hospital in Atlanta, GA, USA
    Postgrad Med 112:17-21. 2002
    ..Selecting the most appropriate insulin regimen and delivery system for patients' individual needs can help patients make a smoother transition to intensive insulin therapy and improve the likelihood of long-term success...
  11. doi request reprint Defining the importance of daily glycemic control and implications for type 2 diabetes management
    Bruce W Bode
    Atlanta Diabetes Associates, Atlanta, GA 30309, USA
    Postgrad Med 121:82-93. 2009
    ..Dipeptidyl peptidase-4 inhibitors have the potential to play a vital role in diabetes management at all stages of the disease...
  12. pmc Insulin pump use in type 2 diabetes
    Bruce W Bode
    Atlanta Diabetes Associates, 77 Collier Road, Atlanta, GA 30309, USA
    Diabetes Technol Ther 12:S17-21. 2010
    ..CSII may be appropriate for some people with T2DM, especially those for whom MDI therapy has failed...
  13. pmc Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
    B W Bode
    Atlanta Diabetes Associates, Atlanta, GA, USA
    Diabetes Obes Metab 12:604-12. 2010
    ....
  14. doi request reprint Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine
    Bruce W Bode
    Atlanta Diabetes Associates, Atlanta, Georgia, USA
    Endocr Pract 17:271-80. 2011
    ....
  15. ncbi request reprint Liraglutide: a review of the first once-daily GLP-1 receptor agonist
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Rd, Ste 2080, Atlanta, GA 30309, USA
    Am J Manag Care 17:S59-70. 2011
    ..The guidelines prefer GLP-1 agonists over DPP-4 inhibitors because of their actions that promote weight loss and their somewhat greater effectiveness in reducing postprandial glucose excursions...
  16. doi request reprint Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies
    Bruce W Bode
    Atlanta Diabetes Associates, Georgia, USA
    Am J Geriatr Pharmacother 9:423-33. 2011
    ..Managing elderly patients with type 2 diabetes poses particular challenges, so it is important to evaluate the efficacy and tolerability profile of antidiabetic therapies specifically in this patient population...
  17. ncbi request reprint What's ahead in glucose monitoring? New techniques hold promise for improved ease and accuracy
    B W Bode
    Diabetes Resource Center, Atlanta Diabetes Associates, 77 Collier Rd NW, Suite 2080, Atlanta, GA 30309, USA
    Postgrad Med 109:41-4, 47-9. 2001
    ..By combining continuous glucose monitoring data with continuous insulin delivery via an external or an implantable insulin pump, the outlook promises to be much brighter for patients with type 1 diabetes...
  18. ncbi request reprint Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes
    Bruce W Bode
    Diabetes Resource Center, Atlanta Diabetes Associates, 77 Collier Rd NW, Suite 2080, Atlanta, GA 30309, USA
    Postgrad Med 111:69-77; quiz 27. 2002
    ..Careful adjustment of basal and bolus doses and close follow-up, including patient education, are vital to the success of CSII...
  19. ncbi request reprint Patient perception and use of an insulin injector/glucose monitor combined device
    Bruce Bode
    Atlanta Diabetes Associates, 77 Collier Road NW, Suite 2080, Atlanta, GA 30309, USA
    Diabetes Educ 30:301-9. 2004
    ..This clinical trial assessed patient preference, satisfaction, and use of an insulin injector/glucose monitor combination device versus syringes and a separate glucose monitor...
  20. doi request reprint Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections
    Bruce W Bode
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Clin Ther 29:S135-44. 2007
    ..The 2 main methods of achieving this goal are continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDIs) comprising basal and prandial injections...
  21. ncbi request reprint Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio
    Paul C Davidson
    Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
    Endocr Pract 14:1095-101. 2008
    ..To analyze and compare the underlying mathematical models for basal-bolus insulin-dosing guidelines in patients with type 1 diabetes in a retrospective controlled study...
  22. ncbi request reprint Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values
    Bruce W Bode
    Atlanta Diabetes Associates, Georgia, USA
    Diabetes Care 28:2361-6. 2005
    ....
  23. doi request reprint Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study
    Irl B Hirsch
    University of Washington Medical Center Roosevelt, Seattle, Washington 98105, USA
    Diabetes Technol Ther 10:377-83. 2008
    ....
  24. ncbi request reprint Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study
    Philip Raskin
    University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8858, USA
    Diabetes Care 26:2598-603. 2003
    ..Compare the efficacy, safety, and patient satisfaction of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy for patients with type 2 diabetes...
  25. doi request reprint The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes
    John Mastrototaro
    Medtronic Diabetes, Northridge, California 91325 1219, USA
    Diabetes Technol Ther 10:385-90. 2008
    ..The accuracy and efficacy of the Medtronic Diabetes (Northridge, CA) Real-Time (RT)-Continuous Glucose Monitoring (CGM) sensor were analyzed in 72 subjects with type 1 diabetes...
  26. ncbi request reprint Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII
    Irl B Hirsch
    University of Washington, Seattle, WA, USA
    Diabetes Care 28:533-8. 2005
    ..Multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine was compared with continuous subcutaneous insulin infusion (CSII) with aspart in type 1 diabetic patients previously treated with CSII...
  27. doi request reprint Continuous glucose monitoring and intensive treatment of type 1 diabetes
    William V Tamborlane
    N Engl J Med 359:1464-76. 2008
    ..The value of continuous glucose monitoring in the management of type 1 diabetes mellitus has not been determined...
  28. ncbi request reprint Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial
    Ralph A DeFronzo
    University of Texas Health Science Center, Diabetes Division, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
    Diabetes Care 28:1922-8. 2005
    ..This study investigates whether inhaled insulin (INH; Exubera) can achieve target glycemic control in patients failing on diet and exercise...
  29. ncbi request reprint Working to improve care of hospital hyperglycemia through statewide collaboration: the Georgia Hospital Association Diabetes Special Interest Group
    Curtiss B Cook
    Division of Endocrinology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    Endocr Pract 13:45-50. 2007
    ..To review the efforts of the Georgia Hospital Association Diabetes Special Interest Group (DSIG) to develop and disseminate sample clinical guidelines on management of inpatient hyperglycemia...